News Releases, Resources and Multimedia - 2022
November
August
June
May
February
-
Lilly’s bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 (February 11)
January
News Releases, Resources and Multimedia - 2021
December
-
Lilly’s statement on its monoclonal antibody therapies neutralization activity against the Omicron variant of concern (December 20)
-
Lilly's statement on the testing process of COVID-19 antibody therapies against the Omicron variant of concern (December 14)
November
September
-
Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19 (September 15)
August
-
Lilly’s statement on the reopening of distribution for COVID-19 antibody therapies in the U.S. (August 27)
July
June
May
April
-
GotMyShotCampaign.com, a community-wide effort supported by local government, health care, nonprofit and corporate partners to share facts about COVID-19 vaccines
March
February
-
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19 (February 26)
January
News Releases, Resources and Multimedia - 2020
December
-
Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico (December 18)
November
October
-
CEO Dave Ricks shares Lilly's principles of COVID-19 antibody therapy pricing and access (October 28)
-
Infographic: Lilly's access and affordability principles for our neutralizing antibodies (October 28)
-
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 patients published in New England Journal of Medicine (October 28)
-
Infographic: Lilly's COVID-19 quest - key clinical trials for neutralizing antibodies (October 27)
-
Baricitinib has significant effect on recovery time, most effective in COVID-19 patients requiring oxygen (October 8)
-
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs (October 7)
September
-
STAT News: "Three lessons from COVID-19 on accelerating biopharma innovation," by Anne White, Lilly Oncology president (September 18)
-
Lilly and Amgen announce manufacturing collaboration for COVID-19 antibody therapies (September 17)
-
Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting (September 16)
-
Lilly's neutralizing antibodies and COVID-19 fact sheet (September 16)
August
July
-
Wall Street Journal video: "Scientists work to produce COVID-19 treatments under new conditions" (July 20)
-
Politico: "Four ways drug companies can ease racial disparities," by Lilly executives (July 20)
June
-
Lilly begins a Phase 3 clinical trial with baricitinib for hospitalized COVID-19 patients (June 15)
-
Lilly announces start of a Phase 1 study for its second potential COVID-19 antibody treatment (June 8)
-
Lilly begins world's first study of a potential COVID-19 antibody treatment in humans (June 1)
May
April
-
Indianapolis E-Learning Fund sends $1.5 million to Marion County districts and charter schools (April 27)
-
NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options (April 17)
-
Lilly begins clinical testing of therapies for COVID-19 (April 10)
-
Indianapolis E-Learning Fund launches with more than $2.6 million (April 8)
March
-
Lilly update on supply chain reliability and position on stockpiling (March 26)
-
Updates from Lilly on supply of medicines and insulin affordability (March 24)
-
Lilly provides update on clinical trial activities during COVID-19 pandemic (March 23)
-
Media teleconference regarding COVID-19 (March 18; audio only)
-
AbCellera and Lilly to co-develop antibody therapies for the treatment of COVID-19 (March 12)